Part 1: Plenary Forum

Part 2: Industry Summit

Panel Discussion: Next Generation Immunotherapy

Part 3: Breakout Sessions

Session 1: Tumour Microenvironment
Session 2: Immune Checkpoint Modulation for Cancer Therapy
Session 3: Immuno-Oncology Biomarkers
Session 4: Liquid Biopsy for Immuno-Oncology
Session 5: Next Generation CAR-T and T Cell Therapies
Session 6: Therapeutic Antibodies for Cancer
Session 7: Bispecific and Multi-Specific Antibodies
Session 8: Emerging Immunotherapy Targets
Session 9: Neoantigen Targeted Therapies
Session 10: Cytokine Therapeutics
Session 11: Combination Immunotherapy
Session 12: Cancer Vaccines
Session 13: Immunotherapy for solid tumours
Session 14: Oncolytic Virus Immunotherapy
Session 15: Preclinical and Translational Immuno-Oncology
Session 16: Cellular Models For Immunotherapy
Session 17: Clinically-Relevant Mouse Models
Session 18: Immuno-Oncology Clinical Trials
Session 19: Patterns of Response and Progression to Immunotherapy
Session 20: Protein Engineering for Next-Gen Immunotherapies
Session 21: Small Molecules and Adcs for Emerging Immunotherapy Targets
Session 22: Nanomedicine and Macroscale Materials in Immuno-Oncology
Session 23: AI and Big Data in Immuno-Oncology
Session 24: Immuno-Oncology Investing & Partnering

Part 4: Training Courses

Clinical Skills Training for Immuno-Oncology

Part 5: Exhibition & Company Showcase

Part 6: Matchmaking

Part 7: Social Activities
Part 8: Business Visitingto Local Industry Park or Company